BMS Releases New Results from Late-Stage Psoriasis Drug Trials

Bristol Myers Squibb (BMS) has reported positive findings from two late-stage clinical trials of deucravacitinib, its experimental treatment for moderate-to-severe plaque psoriasis.

Data from the two studies have yet to be peer-reviewed, but BMS claims the drug demonstrated superior skin clearance when going head-to-head with Amgen’s blockbuster Otezla (apremilast).

The oral selective tyrosine kinase 2 (TYK2) inhibitor works by blocking the IL-12, IL-23 and Type-1 interferon pathways affecting the onset of psoriasis.

The company believes the drug could become a new standard of care for plaque psoriasis patients who require systemic therapy. BMS is also eyeing the drug as a potential treatment for other immune-mediated diseases.